Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β2 adrenergic agonist
Artur Wnorowski(Medical University of Lublin), Irving W. Wainer(Cooper Medical School of Rowan University)
Cited by 12
Related Papers
(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
|Anesthesiology|2014|115
β2-Adrenergic Receptor Agonists Inhibit the Proliferation of 1321N1 Astrocytoma Cells
|Journal of Pharmacology and Experimental Therapeutics|2010|39
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot study
|Scientific Reports|2020|38
Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications
|Neurotoxicity Research|2017|36
Cannabinoid Receptor Activation Correlates with the Proapoptotic Action of the β2-Adrenergic Agonist (R,R′)-4-Methoxy-1-Naphthylfenoterol in HepG2 Hepatocarcinoma Cells
|Journal of Pharmacology and Experimental Therapeutics|2012|19